Future perspectives for the development of P-glycoprotein modulators (Q40271710)

19 September 2017

title

Future perspectives for the development of P-glycoprotein modulators (English)

1 reference

19 September 2017

3

Bates SE

1 reference

19 September 2017

Sandor V

1

1 reference

19 September 2017

Fojo T

series ordinal

2

1 reference

19 September 2017

language of work or name

1 reference

1 January 1998

1 reference

19 September 2017

published in

Drug Resistance Updates

1 reference

19 September 2017

volume

1

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

190-200

1 reference

The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia.

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Clinical multidrug resistance in cancer: a multifactorial problem

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Expression of a multidrug resistance gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Clinical trials of P-glycoprotein reversal in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Flow cytometric analysis of the multiple drug resistance phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Modulation of drug permeability in chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

The role of MDR-1 in refractory lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

P-glycoprotein in Adult Hematologic Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Expression of the MDR1 gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Clinical Significance of Multi-Drug Resistance Associated Protein and P-Glycoprotein in Patients with Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

MDR1 gene expression and prognostic factors in primary breast carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Modifiers of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Phase I and pharmacokinetic study of D-verapamil and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

The effect of verapamil on the pharmacokinetics of adriamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Decreased potency of MDR-modulators under serum conditions determined by a functional assay

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Serum can inhibit reversal of multidrug resistance by chemosensitisers

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Mutually co-operative interactions between modulators of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Saturation reversal of the multidrug pump using many reversers in low-dose combinations.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Kinetics of the multidrug transporter (P-glycoprotein) and its reversal

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980039-3

7 January 2021

10.1016/S1368-7646(98)80039-3

Identifiers

DOI

1 reference

19 September 2017

1 reference